1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Fracture - Pipeline Review, H1 2014

Fracture - Pipeline Review, H1 2014

  • March 2014
  • -
  • Global Markets Direct
  • -
  • 75 pages

Fracture - Pipeline Review, H1 2014

Summary

Global Markets Direct’s, ‘Fracture - Pipeline Review, H1 2014’, provides an overview of the Fracture’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Fracture, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fracture and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Fracture
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Fracture and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Fracture products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Fracture pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Fracture
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Fracture pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Fracture - Pipeline Review, H1 2014
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Fracture Overview 8
Therapeutics Development 9
Pipeline Products for Fracture - Overview 9
Pipeline Products for Fracture - Comparative Analysis 10
Fracture - Therapeutics under Development by Companies 11
Fracture - Therapeutics under Investigation by Universities/Institutes 13
Fracture - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Fracture - Products under Development by Companies 17
Fracture - Products under Investigation by Universities/Institutes 18
Fracture - Companies Involved in Therapeutics Development 19
Eli Lilly and Company 19
Kuros Biosurgery AG 20
Novartis AG 21
Kolon Life Science, Inc. 22
TissueGene, Inc. 23
Radius Health, Inc. 24
Arcarios BV 25
Escape Therapeutics, Inc. 26
Orbsen Therapeutics Limited 27
OrgaNext Research BV 28
Fracture - Therapeutics Assessment 29
Assessment by Monotherapy Products 29
Assessment by Combination Products 30
Assessment by Target 31
Assessment by Mechanism of Action 34
Assessment by Route of Administration 37
Assessment by Molecule Type 39
Drug Profiles 41
teriparatide - Drug Profile 41
Product Description 41
Mechanism of Action 41
RandD Progress 41
BA-058 - Drug Profile 42
Product Description 42
Mechanism of Action 42
RandD Progress 42
KUR-113 - Drug Profile 45
Product Description 45
Mechanism of Action 45
RandD Progress 45
bimagrumab - Drug Profile 46
Product Description 46
Mechanism of Action 46
RandD Progress 46
(nandrolone decanoate + cholecalciferol) - Drug Profile 48
Product Description 48
Mechanism of Action 48
RandD Progress 48
rusalatide acetate - Drug Profile 49
Product Description 49
Mechanism of Action 49
RandD Progress 49
KLS-Bfr - Drug Profile 52
Product Description 52
Mechanism of Action 52
RandD Progress 52
OsteoStem - Drug Profile 53
Product Description 53
Mechanism of Action 53
RandD Progress 53
TG-B - Drug Profile 54
Product Description 54
Mechanism of Action 54
RandD Progress 54
Stromal Cell Therapy For Fracture Repair - Drug Profile 55
Product Description 55
Mechanism of Action 55
RandD Progress 55
Bone Morphogenetic Protein Modulators - Drug Profile 56
Product Description 56
Mechanism of Action 56
RandD Progress 56
Epoxyeicosatreienoic Acid Analogues for Musculoskeletal Disorders - Drug Profile 57
Product Description 57
Mechanism of Action 57
RandD Progress 57
Drugs to Modulate PPAR-Delta for Musculoskeletal Disorders - Drug Profile 58
Product Description 58
Mechanism of Action 58
RandD Progress 58
Hydroxyprostaglandin E2 Analogues for Musculoskeletal Disorders - Drug Profile 59
Product Description 59
Mechanism of Action 59
RandD Progress 59
Fracture - Recent Pipeline Updates 60
Fracture - Dormant Projects 64
Fracture - Discontinued Products 65
Fracture - Product Development Milestones 66
Featured News and Press Releases 66
Mar 11, 2013: Merck Provides Update On Fosamax Product Liability Trial 66
Feb 11, 2013: UCB And Amgen Decide Not To Pursue Phase III Clinical Trial Program For CDP7851 66
Jan 07, 2013: Radius Provides Update On Pivotal Phase III Program For BA058-SC Injection 67
Oct 15, 2012: Daiichi Sankyo Announces Positive Phase III Study Results For Denosumab On Fracture Risk In Japanese Patients With Osteoporosis At ASBMR 67
Aug 07, 2012: Lilly Announces Study Results Regarding Postmenopausal Women With Back Pain Caused By Vertebral Fractures 68
Jan 24, 2011: Kuros Reports One Year Data From Phase IIb Study With KUR-111 69
Jun 02, 2010: Kuros Completes Patient Recruitment In A Phase IIB Trial Of KUR-113 In Patients With Tibial Shaft Fractures 70
Jun 01, 2010: Amgen Receives FDA Approval For Prolia For Treatment Of Postmenopausal Women With Osteoporosis At High Risk For Fracture 71
Mar 15, 2010: Kuros Meets Primary Efficacy Endpoint In Phase IIb Study With KUR-111 72
Jun 08, 2009: Kuros Completes Patient Recruitment In A Phase IIb Trial Of KUR-111 In Patients With Tibial Plateau Fractures 73
Appendix 74
Methodology 74
Coverage 74
Secondary Research 74
Primary Research 74
Expert Panel Validation 74
Contact Us 75
Disclaimer 75

List of Tables

Number of Products under Development for Fracture, H1 2014 9
Number of Products under Development for Fracture - Comparative Analysis, H1 2014 10
Number of Products under Development by Companies, H1 2014 12
Number of Products under Investigation by Universities/Institutes, H1 2014 13
Comparative Analysis by Late Stage Development, H1 2014 14
Comparative Analysis by Clinical Stage Development, H1 2014 15
Comparative Analysis by Early Stage Development, H1 2014 16
Products under Development by Companies, H1 2014 17
Products under Investigation by Universities/Institutes, H1 2014 18
Fracture - Pipeline by Eli Lilly and Company, H1 2014 19
Fracture - Pipeline by Kuros Biosurgery AG, H1 2014 20
Fracture - Pipeline by Novartis AG, H1 2014 21
Fracture - Pipeline by Kolon Life Science, Inc., H1 2014 22
Fracture - Pipeline by TissueGene, Inc., H1 2014 23
Fracture - Pipeline by Radius Health, Inc., H1 2014 24
Fracture - Pipeline by Arcarios BV, H1 2014 25
Fracture - Pipeline by Escape Therapeutics, Inc., H1 2014 26
Fracture - Pipeline by Orbsen Therapeutics Limited, H1 2014 27
Fracture - Pipeline by OrgaNext Research BV, H1 2014 28
Assessment by Monotherapy Products, H1 2014 29
Assessment by Combination Products, H1 2014 30
Number of Products by Stage and Target, H1 2014 33
Number of Products by Stage and Mechanism of Action, H1 2014 36
Number of Products by Stage and Route of Administration, H1 2014 38
Number of Products by Stage and Molecule Type, H1 2014 40
Fracture Therapeutics - Recent Pipeline Updates, H1 2014 60
Fracture - Dormant Projects, H1 2014 64
Fracture - Discontinued Products, H1 2014 65

List of Figures

Number of Products under Development for Fracture, H1 2014 9
Number of Products under Development for Fracture - Comparative Analysis, H1 2014 10
Number of Products under Development by Companies, H1 2014 11
Comparative Analysis by Early Stage Products, H1 2014 16
Assessment by Monotherapy Products, H1 2014 29
Number of Products by Top 10 Target, H1 2014 31
Number of Products by Stage and Top 10 Target, H1 2014 32
Number of Products by Top 10 Mechanism of Action, H1 2014 34
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 35
Number of Products by Top 10 Route of Administration, H1 2014 37
Number of Products by Stage and Top 10 Route of Administration, H1 2014 38
Number of Products by Top 10 Molecule Type, H1 2014 39
Number of Products by Stage and Top 10 Molecule Type, H1 2014 40

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025 Summary Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality ...

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Hepatitis C: Kol Insight

September 2016 $ 8085

Download Unlimited Documents from Trusted Public Sources

Anti-Infective Market in Tanzania

  • December 2016
    9 pages
  • Anti-Infective  

  • Tanzania  

    Africa  

View report >

Therapy and Hormone Market in South Korea

  • December 2016
    4 pages
  • Therapy  

    Hormone  

    Cancer  

  • South Korea  

View report >

Opioid Market in the US

  • December 2016
    14 pages
  • Opioid  

  • United States  

View report >

Related Market Segments :

Therapy
Musculoskeletal Disorder

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.